Details for New Drug Application (NDA): 213267
✉ Email this page to a colleague
NDA 213267 describes THALIDOMIDE, which is a drug marketed by Natco and is included in one NDA. Additional details are available on the THALIDOMIDE profile page.
The generic ingredient in THALIDOMIDE is thalidomide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the thalidomide profile page.
The generic ingredient in THALIDOMIDE is thalidomide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the thalidomide profile page.
Summary for 213267
| Tradename: | THALIDOMIDE |
| Applicant: | Natco |
| Ingredient: | thalidomide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 213267
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 150MG | ||||
| Approval Date: | Apr 27, 2023 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 50MG | ||||
| Approval Date: | Apr 24, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Apr 24, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
